FEAF
TWSE

2883 凱基金

36.30 ▲ 0.95 (2.69%) Close · 2026-11-13 · TWSE
Ask about 2883
This is research, not a buy or sell recommendation. Robo-advice in Taiwan requires an FSC licence; FEAF analyses, explains and monitors, and the investor makes the decision. Judgement thresholds are working rules pending review by the team's finance members.

Plain-language summary of valuation, growth, profitability, balance sheet, and recent MOPS filings.

Your risk profile
Conclusion

No strong signal either way in the data reviewed.

For a moderate profile, none of the items above crosses the watch-out thresholds set by the team.

In plain words

For financial-sector company 2883, the free-cash-flow DCF and debt ratio do not apply, while its P/E of 12.69 is close to the Financials and insurance median of 13.50 across 31 listed peers. Revenue fell -12.3% in 2025, but the latest quarter Q2 2026 recorded a year-on-year growth of 10,864.7%, demonstrating moderate profitability with an 11.3% return on equity and a 53.3% net margin. Currently, 1 filing is held or rejected awaiting human review, and no items cross the watch-out thresholds for a moderate profile. The reviewed data shows no strong signal either way, and the final investment decision rests with the investor.

Written by gemini-3.6-flash from the facts above; every number was checked against them.

Strengths

——

Watch-outs

! Revenue fell -12.3% in 2025; latest quarter Q2 2026: 10,864.7% year on year. source (Financials) →

What to check before deciding

?Is the revenue decline temporary or structural?

What the analysis found

· Sector Financial-sector company: the free-cash-flow DCF and the debt ratio do not apply and are left out. source →
· Valuation vs peers P/E 12.69 is close to the Financials and insurance median of 13.50 (31 listed peers). source →
! Growth Revenue fell -12.3% in 2025; latest quarter Q2 2026: 10,864.7% year on year. source →
· Profitability Return on equity 11.3% with a 53.3% net margin: moderate profitability. source →
· Filings 1 filing(s) are held or rejected and wait for human review. source →